Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 18/20 | 0.74 |
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12988949 | 0.86 | LPAR1 (0.72) | LPAR1LPAR3 | |
| SCHEMBL12989367 | 0.86 | LPAR1 (0.72) | LPAR1LPAR3 | |
| SCHEMBL15897414 | 0.86 | LPAR1 (0.72) | LPAR1LPAR3HRH1PDE1CPDE2A | |
| SCHEMBL17083212 | 0.85 | LPAR1 (1.00) | LPAR1LPAR3 | |
| SCHEMBL15897422 | 0.83 | LPAR1 (0.68) | LPAR1LPAR3HRH1 | |
| SCHEMBL17083217 | 0.83 | LPAR1 (0.95) | LPAR1LPAR3HRH1 | |
| SCHEMBL29895996 | 0.82 | LPAR1 (0.63) | LPAR1LPAR3PDE1CPDE2APDE5A | |
| SCHEMBL29896013 | 0.82 | LPAR1 (0.63) | LPAR1LPAR3PDE1CPDE2APDE5A | |
| SCHEMBL13195363 | 0.81 | LPAR1 (0.87) | LPAR1LPAR3 | |
| SCHEMBL12989462 | 0.81 | LPAR1 (0.87) | LPAR1LPAR3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | LPAR1 1/4885LPAR3 5/4885HRH1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.